Maternal treatment with opioid analgesics and risk for birth defects

Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
American journal of obstetrics and gynecology (Impact Factor: 3.97). 02/2011; 204(4):314.e1-11. DOI: 10.1016/j.ajog.2010.12.039
Source: PubMed

ABSTRACT We examined whether maternal opioid treatment between 1 month before pregnancy and the first trimester was associated with birth defects.
The National Birth Defects Prevention Study (1997 through 2005) is an ongoing population-based case-control study. We estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIS) for birth defects categories with at least 200 case infants or at least 4 exposed case infants.
Therapeutic opioid use was reported by 2.6% of 17,449 case mothers and 2.0% of 6701 control mothers. Treatment was statistically significantly associated with conoventricular septal defects (OR, 2.7; 95% CI, 1.1-6.3), atrioventricular septal defects (OR, 2.0; 95% CI, 1.2-3.6), hypoplastic left heart syndrome (OR, 2.4; 95% CI, 1.4-4.1), spina bifida (OR, 2.0; 95% CI, 1.3-3.2), or gastroschisis (OR, 1.8; 95% CI, 1.1-2.9) in infants.
Consistent with some previous investigations, our study shows an association between early pregnancy maternal opioid analgesic treatment and certain birth defects. This information should be considered by women and their physicians who are making treatment decisions during pregnancy.

Download full-text


Available from: Sonja Rasmussen, Jul 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The case-control study design offers an operationally efficient approach to measuring an association between an exposure and an outcome, especially when the outcome is rare, as is true for specific birth defects. For example, instead of following 50,000 pregnant women to have sufficient statistical power to identify a doubling in risk of oral clefts associated with a common exposure (e.g., cigarette smoking), 75 cases and 3 controls per case could be studied with equal statistical power. Examples of case sources include hospital or clinical series, or birth defect registries. For validity, control subjects should represent the population base of the cases, which can be difficult to identify for non-population-based case groups. Case-control studies typically rely on retrospective exposure measurement, which presents a major challenge and sets up the possibility of recall bias. Approaches are discussed to keep sources of bias to a minimum, including recall, non-differential information, and selection biases. Case-control studies can play an important role in this process for both hypothesis-generation and hypothesis-testing of potential teratogens. Examples of case-control studies and their contributions to the field are presented. © 2011 Wiley-Liss, Inc.
    American Journal of Medical Genetics Part C Seminars in Medical Genetics 08/2011; 157(3):201-8. DOI:10.1002/ajmg.c.30307
  • American journal of obstetrics and gynecology 04/2011; 205(3):e12; author reply e12-3. DOI:10.1016/j.ajog.2011.04.026
  • American journal of obstetrics and gynecology 09/2011; 205(3):e10; author reply e10 -1. DOI:10.1016/j.ajog.2011.06.030